Compounds and compositions for the treatment of parasitic diseases
WO2021079195A1
Tim-3 inhibitors and uses thereof
WO2021079188A1
Combination therapies with venetoclax and tim-3 inhibitors
WO2021070090A1
2-azaspiro[3.4]octane derivatives as m4 agonists
WO2021070091A1
5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
WO2021064695A1
Methods for measuring cralbp activity
WO2021064575A1
Treatment comprising the use of fxr agonists
WO2021061898A1
Antiviral pyrazolopyridinone compounds
WO2021057853A1
Aza-quinoline compounds and uses thereof
WO2021055820A1
3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
WO2021053591A1
Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
WO2021053617A1
Mll1 inhibitors and anti-cancer agents
WO2021053618A1
Treatment comprising fxr agonists
WO2021053559A1
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021053560A1
Combination therapy with entpd2 and cd73 antibodies
US2021077430A1
Combination therapy
WO2021053556A1
Nkg2d fusion proteins and uses thereof
WO2021053555A1
Glue degraders and methods of use thereof
WO2021053495A1
Bifunctional degraders and their methods of use
WO2021053489A1
Use of an mdm2 inhibitor for the treatment of myelofibrosis